Dr. Brian Nahed is a neurosurgeon who specializes in Brain Tumors (Glioblastoma, Gliomas, Meningiomas, Metastatic Brain Tumors) and Spinal Disorders. He is Assistant Professor in the Department of Neurosurgery and Pappas Center for Neurooncology.
BiographyDr. Brian Nahed is a neurosurgeon who specializes in brain tumors (glioblastoma, gliomas (low grade and high grade gliomas), metastatic brain tumors, and meningiomas) as well as Spinal Disorders.
Born in New York, Dr. Nahed attended UCLA where he majored in Neuroscience, graduating Phi Beta Kappa. He attended the Yale School of Medicine where he was awarded the Doris Duke Clinical Research Fellowship. Dr. Nahed completed his internship and neurosurgery residency at the Massachusetts General Hospital. Dr. Nahed completed a postdoctoral fellowship with Drs. Daniel Haber and Shyamala Maheswaran at the MGH Cancer Center.
Dr. Brian Nahed joined the MGH Department of Neurosurgery and Brain Tumor Center in 2011. He is an assistant professor and teaching faculty member of Harvard Medical School. Dr. Brian Nahed's research focuses on developing a blood based test to diagnose and monitor brain tumors. In collaboration with Drs. Haber, Maheswaran, and Stott, Dr. Nahed's recently published the first evidence of circulating tumor cells in the blood patients with glioblastoma. Dr. Nahed is actively enrolling patients into his translational clinical research study.
Dr. Brian Nahed is a member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, and serves on national committees forthe Tumor Section and Council State Neurological Societies. He serves as a neurotrauma consultant for the National Football League (NFL).
Circulating Brain Tumor Cells
Metastatic Disease of the Brain and Spine
Dr. Brian Nahed's research focuses on identifying and analyzing circulating tumor cells in the blood of patients with brain cancer. Through a collaboration between bioengineers, molecular biologists and clinicians, a circulating tumor cell capture device was developed to capture and detect tumor cells from patients with cancer. Under the mentorship of Drs. Daniel Haber, Shyamala Maheswaran, and Mehmet Toner, they aim to harness this technology to genetically characterize tumor cells without needing an invasive biopsy, and determine responsiveness to targeted cancer drugs. It also offers the opportunity to study cancer stem cells or metastasic precursors, thought to be at the origin of cancer spread via the bloodstream, to define their molecular vulnerabilities and help design new therapies to prevent cancer metastasis.
Dr. Nahed's research was recently published in Cancer Discovery and he is active enrolling patients in his translational clinical research study.
87 peer-reviewed publications to date. Please refer to pub med link for articles.